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Methotrexate in Severe Ankylosing Spondylitis: An Open Study
MARJONNE C.W. CREEMERS, MARCEL J.A.M. FRAN SS EN, LEVINUS B.A. van de PUTTE,
FRANK W.J. GRIB N AU, and PIET L.C.M. van RIEL
ABSTRACT. Objective. To study the efficacy and toxicity of methotrexate (MTX) for patients with ankylosing
spondylitis (AS) in a 36 week, open, single observer study.
Methods. Patients were selected for study if they had evidence of active disease and had failed to 
respond to treatment with nonsteroidal antiinflammatory drugs (NSAID) and sulfasalazine. Eleven 
patients entered the study, and 9 were evaluated at the end. Oral MTX (7.5-15 mg weekly) was 
given for at least 24 weeks; NSAID were kept at a stable dose. Efficacy was evaluated by calculat­
ing the relative difference of assessed variables between Weeks 0 and 24 and by patient evaluation. 
Results. Assessed variables showed good relative improvement. Four patients decided to continue 
MTX; 3 used a lower dose of NSAID; one stopped NSAID. Five patients discontinued MTX: 3 
of these had disease flares and restarted MTX. Side effects were mild and reversible. 
Conclusion. Results of our study showed that the majority of our patients with AS taking MTX 
had beneficial effects. [J Rheumatol 1995;22:1104-1)
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Ankylosing spondylitis (AS) is a chronic inflammatory con­
dition of the axial skeleton and sacroiliac joints that may lead 
to spinal ankylosis1. Peripheral arthritis and extraarticular 
features occur in a small proportion of cases and are bad 
prognostic factors1»2. Up to now treatment of AS mainly 
comprises nonsteroidal antiinflammatory drugs (NSAID). Of 
second line drugs, only sulfasalazine3 efficacy has been 
established in AS. Significant clinical improvement with 
methotrexate (MTX) administered weekly has been report­
ed in 16 patients with severe AS4"7. The aim of our study 
was to determine the efficacy and toxicity of MTX in patients 
with severe AS in an open, single observer, 36 week inter­
ventional study.
MATERIALS AND METHODS
The study was conducted at the rheumatology departments of University 
Hospital Nijmegen, St. Radboud and St. Maartenshospital Nijmegen with a 
full ethical committee approval.
Patients with severe AS fulfilling the modified New York criteria8, of 
either sex, aged 18 to 60 years, were included. They were excluded in cases 
of (I) serious systemic disease, malignancies, impaired organ function, or 
serious infections like tuberculosis; (2) mental disorders; (3) alcohol or drug
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abuse; (4) pregnancy or breast feeding; (5) history of intestinal disease. 
Severe or refractory AS was defined as a failure on treatment with NSAID 
and sulfasalazine; as well, active disease had to be present, defined as the 
presence or persistence of at least 2 of the following features: (1) morning 
stiffness at least 30 min; (2) disturbed sleep due to pain and stiffness; (3) 
peripheral arthritis; (4) erythrocyte sedimentation rate (ESR) > 30 mm, 
or C-reactive protein (CRP) > 20 mg/1, or IgA > 3 . 9  mg/1; (5) spinal 
pain; (6) stiffness and pain of thorax at movement or during normal breathing;
(7) pain in both buttocks during the night or day. A stable NSAID dose 
and discontinuation of sulfasalazine were required, both for at least 4 weeks 
before study entry. Adequate contraception during and 6 months after MTX 
treatment was recommended.
Study design. This was an open, single observer, 36 week study of MTX 
efficacy and toxicity. Patients were seen every 4 weeks for 36 weeks and 
variables for disease acdvity and toxicity were measured at each visit. Medi­
cation for nonrheumatic chronic conditions and intercurrent acute illnesses 
was allowed, except for antifolate drugs (e.g., sulfonamide derivatives), 
allopurinol, immunosuppressive treatment, and second line drugs. MTX 
was taken orally 7.5 mg/week. At Week 12, MTX dose was increased to 
15 mg/week in case of lack of response. At Week 24, efficacy was evalu­
ated based on patients’ global assessment: (1) if patients judged that MTX 
was clearly effective, MTX was kept at a stable dose and NSAID dose was 
reduced; and (2) if patients judged efficacy of MTX was moderate or absent 
(see below), MTX was discontinued and NSAID kept at a stable dose. If 
the disease flared subsequently, judged by the patients’ global assessment 
and according to predefined criteria for disease activity, MTX was restart­
ed. In case of severe side effects, MTX was stopped; in milder cases the 
dose was decreased or 1 mg folic acid was administered9-11.
Measurements. Every visit the following variables were assessed. (1) Ob­
jective clinical variables: occiput-wall distance, chest expansion, Schober’s
10 cm test12, fingertip-to-floor distance, an enthesis index13, number of 
swollen joints, Ritchie Articular Index14. Extraarticular manifestations were 
carefully monitored. (2) Subjective variables: visual analog scales (VAS) 
ranging from 0 to 100 mm, corresponding with “ none” to “ has never been 
worse,” were used for spinal pain, chest pain, general well being, and tired­
ness. Next, duration of morning stiffness after arising was assessed. (3) 
Functional assessment: a Dutch Functional Index (DFI) for AS15. (4) 
Laboratory variables: ESR, CRP, complete blood cell count, serum creati­
nine, liver function tests, albumin, immunoglobulin A, G, and M, creatinine
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ptiosphokinase. (5) Side effects related to study medication were assessed 
by direct questioning or as spontaneously reported complaints.
Response. The relative difference between Weeks 0 and 24 was calculated, 
and response was defined as follows: good, if improvement > 5 0 %  was 
present in the majority of variables; moderate, if this improvement was 
between 15 and 50%; and no response, in case changes were smaller or 
absent. Variables not abnormal at the start of the study or during the study 
were defined as “ not affected” (NA) and left out of the evaluation.
RESULTS
In total, 11 patients were enrolled in the study; all had NSAID 
failure, 9 failed to respond to sulfasalazine treatment and 2 
could not tolerate sulfasalazine, one patient used cor­
ticosteroids (15 mg/ week) and continued this throughout the 
study. Patients’ characteristics are shown in Table 1. After 
12 weeks of treatment, MTX was increased to 15 mg weekly 
iß 9 patients. Generally, response, if present, could be ob­
served after 4 to 12 weeks of MTX treatment. Two patients 
dropped out at Week 16 because of protocol violating changes 
in treatment: one due to a flare of the disease, the other due 
to development of a peptic ulcer, for which oral steroids were 
stopped as well.
Table 1. Patientss characteristics at start of the study
* No. Patients
Male; female 8:3
HLA-B27 positivity l í
Peripheral arthritis 3
Enthesitis 5
Iridocyclitis 2
Age {yrs)* 35 ± 8 (21-47)
Disease duration 14 ± 9 (3-26)
* Mean ± standard deviation (range).
After 24 weeks, 9 patients were evaluable, with a mean 
weekly MTX dose of 13.3 mg over a period of 24 weeks. 
Improvement could be seen in most assessed variables (Table
2 and Figure 1). CRP and ESR improved equally. Immuno­
globulin A, elevated in 4 patients, decreased. Anemia (Hb: 
5.7 to 6.7 mmol/l), present in all 3 patients with peripheral 
arthritis, improved at least 1.0 mmol/l. The course of iridocy­
clitis (2 patients, 3 episodes) appeared not to be influenced 
by MTX. Efficacy was good in 5 patients: 4 continued MTX 
treatment and the NSAID dose could be reduced (n = 3) 
or stopped (n = 1). The 5th patient stopped MTX treatment 
despite good clinical response, but deteriorated within 4 
weeks, and MTX was readministered. In the remaining 4 
patients MTX was stopped because of moderate or absent 
efficacy, and 2 of them deteriorated within 4 weeks.
Side effects were abdominal discomfort (n = 2), nausea 
(n = 1), transient oral ulcers (n = 1), reversible liver func­
tion elevations (n = 3), for which 2 patients experienced 
benefit with folic acid 1 mg.
DISCUSSION
MTX was studied in severe AS in a 36 week open study. 
Regarding enthesitis, peripheral arthritis, and duration of the 
disease, patients were quite different. Data were not ana­
lyzed statistically because of this heterogeneity and the small 
sample size. Efficacy was evaluated in 2 different 
ways: objectively, i.e., the relative difference of assessed 
variables between Weeks 0 and 24 (Table 2); and subjec­
tively, by deciding at Week 24 to either continue (n = 4) 
or stop MTX (n = 5) based on patients5 global assessment. 
One patient was able to stop NSAID treatment, 3 were able
Table 2. Relative improvement*
Variables
1 3 4
Patients 
5 6
1
7 8 9 10
Disease duration (yrs) 23 26 g 8 5 22 16 11 3
Disease characteristics** P P P I
Spinal pain + ~h + + + — + — + +
Chest pain + + — + Hh — + + — — + +
General well being + + + + + + + + + — — —
Tiredness Hr + + + + + + — — — — —
Morning stiffness + + + + + + — — — ++
Occiput-to-wall distance + + + NA NA — NA NA NA
Fingertip'to-floor distance + + — — + + — — — ■njw h| It
Chest expansion + + — + + + + — — —
Schober’s 10 cm test + + + + + + — — — + +
Ritchie Articular Index + + + + NA + + + -h + NA — NA
Number of swollen joints NA + NA + + NA -h + NA NA NA
Enthesis index + + + + + + -f- — — — NA
Dutch Functional Index + -H — + + + + + — — —
ESR + 4- _j_ _j~ NA + NA — —
* Relative improvement: ++ improvement >  50%; + improvement 15-49%; — no improvement or <15%;  
NA = not affected.
** P = peripheral arthritis; I = iridocyclitis.
Patients 2 and 11 dropped out; both had enthesitis, Patient 2 also had iridocyclitis.
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Fig. L Response in the 9 evaluable patients (Week 0-24).
to reduce the NSAID dose, and 4 patients deteriorated after 
discontinuation of MTX and chose to restart. Side effects 
were reversible or transient, and no severe side effects were 
seen. There was no obvious difference in response between 
patients with peripheral arthritis and patients with involve­
ment of the axial skeleton only. Thus, although numbers were 
small, this study provides circumstantial evidence that the 
majority of patients experienced beneficial effects after tak­
ing MTX. In future, a double blind, placebo controlled study 
should corroborate these data.
REFERENCES
1. Heliwell PS, Wright V: Ankylosing spondylitis. In: Bellamy N, 
ed. Prognosis in Rheumatic Diseases. Kluwer Academic 
Publishers, 1991:133-52,
2. Carette S: The natural disease course of ankylosing spondylitis. 
Arthritis Rheum 1983;26:186-90.
3. Bosi Ferraz M, Tugwell P, Goldsmith CH, Atra E: Meta­
analysis of sulfasalazine in ankylosing spondylitis. J Rheumatol 
1990; 17:1482-6.
4. Bosi Ferraz M, Carrica da Silva H, Atra E: Low dose 
methotrexate with leucovorin rescue in ankylosing spondylitis. 
J Rheumatol 1991; 18:146-7.
5. Handler RP; Favorable results using methotrexate in treatment 
of patients with ankylosing spondylitis (letter). Arthritis Rheum 
1989;32:234.
6. Yamane K, Saito C, Natsuda H, et al: Ankylosing spondylitis 
successfully treated with methotrexate. Intern Med
1993;32:53-6.
7. Sampaios-Barros PD, Costallat LTL, Fernandes SRM, et al: 
The use of methotrexate in the treatment of ankylosing 
spondylitis: Pilot study. Rev Esp Reumatol 1993;{suppl 
1)20:485.
8. van der Linden S, Valkenburg HA, Cats A: Evaluation of 
diagnostic criteria for ankylosing spondylitis: A proposal for 
modification of the New York criteria. Arthritis Rheum
79S4;27:361-8.
9. Tishler M, Caspi D, Fishel B, Yaron M: The effect of
1106 The Journal of Rheumatology 1995; 22:6
leucovorin (folinic acid) on methotrexate therapy in rheumatoid 
arthritis patients. Arthritis Rheum 1988;31:906-8.
10. Morgan S, Bagott JE, Vaughn WH, Young PK, Austin JV, 
Krumdieck CL: The effect of folic acid supplementation on the 
toxicity of low-dose methotrexate in patients with rheumatoid 
arthritis. Arthritis Rheum 1990;33:9-18.
11. Joyce DA» Will RK, Hoffman DM, Laing B, Blackbourn SJ: 
Exacerbation of rheumatoid arthritis in patients treated with 
methotrexate after administration of folinic acid. Ann Rheum 
Dis 1991; 50:913-4.
12. Schober P: Lendenwirbelsaule und Kreuzschmerzen. Muench 
Med Wschr 7937;84:336-9.
Creemers} et al: MTX in severe AS
13. Mander MM, Simpson JM, McLellan A, Walker D, Goodacre 
JA, Dick WC: Studies with an enthesis index as a method of 
clinical assessment in ankylosing spondylitis. Ann Rheum Dis
1987;46:197-202.
14. Ritchie DM, Boyle JSA, Mclnnes JM, et al: Clinical studies 
with an articular index for the assessment of joint tenderness in 
patients with rheumatoid arthritis. Q J  Med 1968; 147:393-406.
15. Creemers MCW, van’t Hof MA, Franssen MJAM, van de 
Putte LB A, Gribnau FWJ, van Riel PLCM: A Dutch version of 
the functional index for ankylosing spondylitis; Development 
and validation in a long-term study. Br J Rheumatol
1994;33:842-6.
4
1107
